• Selection of news and upcoming events

COVID-19 Long-Hauler Therapy Space Beginning to Take Shape



It’s the chronic disease that will likely define the first half of this decade – and it’s already all too familiar to many COVID-19 survivors. While the space is just beginning to emerge, therapies for long-haul COVID-19 patients are still very much an unmet need.

So first, what exactly is a COVID-19 long-hauler?


“If you look at the CDC’s website, it says that if you have a mild case of COVID-19 you could expect to recover in about two weeks. So, it starts to tell us that if people are taking longer than two weeks to feel better, they’re starting to get into that long-haulers zone. From what I’ve seen is, most of the people that I’m collecting data on, they’ve been sick for actually many, many months,” said Dr. Natalie Lambert, Ph.D., an associate research professor in biostatistics at the Indiana University School of Medicine, on a recent episode of Rooney Partners (RP) HealthCast.


While there are a myriad of symptoms associated with the illness often referred to as long COVID, including brain fog and fatigue, a large number of the therapies currently in development are geared toward the lasting lung fibrosis and respiratory problems.

Throughout the past couple of months, BioSpace has spoken with a number of companies dipping their toes into these waters, including Organicell Regenerative Medicine Inc, PureTech Health Plc., CytoDyn Inc. and Bionano Genomics.


PureTech Targets Lymphatic Flow Disorders – Including Long COVID

On December 3, PureTech, a clinical-stage biotherapeutics company nestled in the Cambridge-Boston biotech hub, announced the commencement of a global Phase II trial evaluating its lead product candidate, LYT-100, in Long COVID respiratory complications and related sequelae.

Please, to access the full article visit Bio Space


biotechdesign.io